Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation.
Tranexamic acid is one of the widely used antifibrinolytic agents. In spite of its effective inhibitory activity against plasminogen, thromboembolic adverse events caused by tranexamic acid are rare. We encountered three recipients of allogeneic hematopoietic stem cell transplantation (HSCT) who developed hepatic veno-occlusive disease (VOD) shortly after the administration of tranexamic acid. Hepatic VOD was resolved completely in all patients with the discontinuation of the drug, and with supportive measures with or without intravenous tissue plasminogen activator administration. These findings suggest that administration of tranexamic acid could be one of the possible risk factors for developing hepatic VOD in HSCT recipients.
Mori
Takehiko
T
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. tmori@sc.itc.keio.ac.jp
Aisa
Yoshinobu
Y
Shimizu
Takayuki
T
Yamazaki
Rie
R
Mihara
Ai
A
Yajima
Tomoharu
T
Hibi
Toshifumi
T
Ikeda
Yasuo
Y
Okamoto
Shinichiro
S
D000933:Antifibrinolytic Agents / Q000009:adverse effects*; D001663:Bilirubin / Q000097:blood; D002648:Child; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006504:Hepatic Veno-Occlusive Disease / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use; D014148:Tranexamic Acid / Q000009:adverse effects*; D016896:Treatment Outcome
D000933:Antifibrinolytic Agents; D011994:Recombinant Proteins; D014148:Tranexamic Acid; D010959:Tissue Plasminogen Activator; D001663:Bilirubin